Brief: Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy
17/06/2024 13:51
June 17 (Reuters) - Fortress Biotech Inc FBIO.O :
* MUSTANG BIO ANNOUNCES FAVORABLE EFFICACY AND SAFETY DATA
FROM
COMPLETE WALDENSTROM MACROGLOBULINEMIA COHORT OF PHASE 1/2
CLINICAL TRIAL OF MB-106, CD20-TARGETED AUTOLOGOUS CAR-T THERAPY
* MUSTANG BIO INC: OVERALL RESPONSE RATE OF 90% IN COHORT
WITH
DURABLE RESPONSES OBSERVED; ONE PATIENT REMAINS IN COMPLETE
REMISSION AT 31 MONTHS
Source text for Eikon: ID:nGNXbnM0Fd
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi